transmembrane protein 87AGenealiases: ELKIN1 · GOLPHCAT
Q-omics provides the consensus-scored TMEM87A profile across patient tissues and cancer cell-line models. TMEM87A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM87A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TMEM87A RNA expression shows 21,017 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where TMEM87A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM87A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM87A survival associations across molecular data types. TMEM87A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM87A RNA expression–survival associations across cancer types. High TMEM87A expression shows unfavorable associations in UVM, HNSC, ACC, KIRP and PAAD, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM87A RNA expression.
This table summarizes TMEM87A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM87A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM87A shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, KIRC, LIHC and BLCA. The HNSC box plot shows higher TMEM87A RNA expression in tumor versus normal tissue (log2 FC = +1.104, t-test p < 0.001).
This table shows molecular features associated with TMEM87A in patient tissues and cancer cell lines. In patient samples, TMEM87A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM87A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
